quantisnow
FeedTopReportsPricing
⌘K
Live feed
11:39:07·1065d
FDARegulatory
Opiant Pharmaceuticals Inc. logo

FDA Approval for OPVEE issued to OPIANT PHARMACEUTICALS INC

OPNT· Opiant Pharmaceuticals Inc.
Health Care
Original source

Companies

  • OPNT
    Opiant Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Dec 9UpdateOppenheimer$42.00

Related

  • FDA1067d
    May 22, 2023 - FDA Approves Prescription Nasal Spray to Reverse Opioid Overdose
  • FDA1067d
    FDA Approval for OPVEE (nalmefene) issued to OPIANT PHARMACEUTICALS INC
  • SEC1137d
    SEC Form 15-12G filed by Opiant Pharmaceuticals Inc.
  • SEC1141d
    SEC Form EFFECT filed by Opiant Pharmaceuticals Inc.
  • SEC1141d
    SEC Form EFFECT filed by Opiant Pharmaceuticals Inc.
  • SEC1141d
    SEC Form EFFECT filed by Opiant Pharmaceuticals Inc.
  • INSIDER1147d
    SEC Form 4: Silver Gabrielle Alison returned $466,860 worth of shares to the company (23,343 units at $20.00), closing all direct ownership in the company
  • INSIDER1147d
    SEC Form 4: Collard Craig A returned $1,116,440 worth of shares to the company (55,822 units at $20.00), closing all direct ownership in the company
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022